- Spain CIMA (Spanish): search for “imidapril” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- History of angioedema (ACE inhibitor, hereditary, acquired or idiopathic)
- Pregnancy
- AN69 hemodialysis; dextran sulfate or similar apheresis
- Aliskiren with diabetes or GFR <60
- Sacubitril/valsartan within 36 hours
- Hypersensitivity
Dosing: Adult
- Hypertension, including renal parenchymal hypertension: 5 to 10 mg once daily; start 2.5 mg in severe hypertension, kidney impairment or renal parenchymal hypertension
Dosing: Altered kidney function
Imidapril is an ACE inhibitor whose active metabolite is excreted in urine. The Singapore product information starts at 2.5 mg once daily in kidney impairment and, at creatinine clearance (CrCl) below 30 mL/min or serum creatinine above 3 mg/dL, advises halving the dose or extending the interval because accumulation can cause hypotension and further kidney decline. Hemodialysis with AN69 membranes is contraindicated. It has no US FDA label.
Kidney function measure: Singapore product information uses creatinine clearance (CrCl, mL/min) or serum creatinine (above 3 mg/dL).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 5 to 10 mg once daily (Singapore NDF).
- CrCl 30–59 mL/min
- Hypertension with kidney impairment: start 2.5 mg once daily and titrate (Singapore NDF). Monitor potassium and creatinine.
- CrCl 15–29 mL/min
- CrCl <30 mL/min (or serum creatinine above 3 mg/dL): use with care; consider halving the usual dose or extending the dosing interval. Start at 2.5 mg once daily in hypertension with kidney impairment (Singapore NDF). Monitor potassium and creatinine.
- CrCl <15 mL/min (not on dialysis)
- CrCl <30 mL/min (or serum creatinine above 3 mg/dL): use with care; consider halving the usual dose or extending the dosing interval. Start at 2.5 mg once daily in hypertension with kidney impairment (Singapore NDF). Monitor potassium and creatinine.
- Hemodialysis (intermittent)
- Hemodialysis with AN69 (polyacrylonitrile) membranes is contraindicated (anaphylactoid reactions). Dose as for CrCl <30 (half dose or longer interval); no dialysis-specific dosing given (Singapore NDF).
- Peritoneal dialysis
- Dose as for CrCl <30; no PD-specific data.
- CRRT
- No data; avoid starting ACE inhibitors in acute kidney injury.
- Dialyzable? Not stated.
- Monitoring Potassium and creatinine after starting and dose changes; blood pressure (excess hypotension); angioedema (Singapore NDF). Recheck creatinine and potassium after starting or increasing the dose; continue unless creatinine rises by more than 30% within 4 weeks, and investigate larger rises (renal artery stenosis, volume depletion, NSAIDs). Continue even when eGFR falls below 30 unless not tolerated (KDIGO 2024).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: Singapore NDF product information (October 9, 2026). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not stated in the source.
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Tablet: 5 mg, 10 mg
Registered products in the Philippines
4 products registered with the Food and Drug Administration (FDA) Philippines list Imidapril as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products4
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
NortenImidapril Hydrochloride | 10 mg TabletFlex foil Strip x 10's Box of 100's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DR-XY23294 | Jul 6, 2028 | |
NORTENImidapril Hydrochloride | 5 mg TabletAluminum Foil Strip x 10's Box of 100's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DR-XY23293 | Sep 14, 2027 | |
VascorImidapril Hydrochloride | 10 mg TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY23799 | Jul 6, 2028 | |
VascorImidapril Hydrochloride | 5 mg TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY23798 | Jul 26, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Aliskiren (diabetes or GFR <60) | Avoid | Stroke, kidney impairment, hyperkalemia, hypotension. | Contraindicated unless blood pressure is markedly uncontrolled. |
| Sacubitril/valsartan | Avoid | Angioedema. | Contraindicated; separate by 36 hours. |
| AN69 dialysis membranes; dextran sulfate LDL apheresis | Avoid | Anaphylactoid reactions, shock. | Contraindicated. |
| Potassium-sparing diuretics, mineralocorticoid receptor antagonists, potassium supplements, salt substitutes, trimethoprim | Adjust or monitor | Hyperkalemia. | Monitor potassium. |
| NSAIDs including COX-2 inhibitors | Adjust or monitor | Acute kidney injury; less blood-pressure effect. | Avoid regular use; monitor creatinine. |
| Lithium | Adjust or monitor | Higher lithium levels. | Monitor lithium levels. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Dry cough (ACE inhibitor class effect)
Serious
- Angioedema
- Hyperkalemia; worsening kidney function
- Excessive hypotension
Monitoring parameters
- Potassium and creatinine after starting and dose changes; blood pressure (excess hypotension); angioedema (Singapore NDF). Recheck creatinine and potassium after starting or increasing the dose; continue unless creatinine rises by more than 30% within 4 weeks, and investigate larger rises (renal artery stenosis, volume depletion, NSAIDs). Continue even when eGFR falls below 30 unless not tolerated (KDIGO 2024). Kidney
- Potassium, creatinine, blood pressure
Pharmacokinetics
Key PK parameters
| Active metabolites | Imidaprilat |
|---|---|
| Renal excretion kidney | Urinary (reduced in kidney impairment); percentage not stated |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Ministry of Health Singapore (National Drug Formulary). Tanatril tablets 10 mg product information (SIN10614P) [Singapore NDF product information, October 9, 2026; no US FDA label]. https://www.ndf.gov.sg/about-drugs/product-information/SIN10614P/
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Ministry of Health Singapore. (2026). Tanatril tablets 10 mg (imidapril hydrochloride) [SIN10614P; National Drug Formulary product information; last updated October 9, 2026]. https://www.ndf.gov.sg/about-drugs/product-information/SIN10614P/
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .